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Hepatitis Awareness Month and 
Testing Day — May 2019
May is designated as Hepatitis Awareness Month, 
and May 19 is Hepatitis Testing Day. Hepatitis B and 
hepatitis C, the most common types of viral hepatitis in 
the United States, can cause chronic infections, and many 
persons remain unaware of their infection until serious 
complications occur. In 2016, an estimated 862,000 
and 2.4 million persons were living with hepatitis B and 
hepatitis C, respectively, despite availability of a vaccine 
and effective treatment for hepatitis B and a cure for 
hepatitis C (1,2).
Although hepatitis A is preventable through vaccina-
tion, multiple states have had outbreaks since 2016, with 
unprecedented large numbers of cases and person-to-
person spread (primarily among persons who use drugs or 
experience homelessness). A report in this issue of MMWR 
summarizes this resurgence of hepatitis A among unvac-
cinated adults at risk (3).
New cases of hepatitis C are also increasing; during 
2010–2016, they increased 3.5-fold, mostly among young 
adults (4). Recent increases in viral hepatitis infections, 
many attributed to surges in injection-drug use (4), high-
light the importance of acknowledging and combatting the 
infectious disease consequences of the nation’s opioid crisis.
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Increase in Hepatitis A Virus 
Infections — United States, 
2013–2018
Monique A. Foster, MD1; Megan G. Hofmeister, MD1;  
Benjamin A. Kupronis, MPH1; Yulin Lin, MD1; Guo-Liang Xia, MD1; 
Shaoman Yin, PhD1; Eyasu Teshale, MD1
Hepatitis A virus (HAV) is primarily transmitted fecal-orally 
after close contact with an infected person (1); it is the most 
common cause of viral hepatitis worldwide, typically causing 
acute and self-limited symptoms, although rarely liver failure 
and death can occur (1). Rates of hepatitis A had declined 
by approximately 95% during 1996–2011; however, during 
2016–2018, CDC received approximately 15,000 reports of 
HAV infections from U.S. states and territories, indicating 
a recent increase in transmission (2,3). Since 2017, the vast 
majority of these reports were related to multiple outbreaks 
of infections among persons reporting drug use or homeless-
ness (4). In addition, increases of HAV infections have also 
occurred among men who have sex with men (MSM) and, 
to a much lesser degree, in association with consumption of 
imported HAV-contaminated food (5,6). Overall, reports of 
hepatitis A cases increased 294% during 2016–2018 compared 
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with 2013–2015. During 2016–2018, CDC tested 4,282 
specimens, of which 3,877 (91%) had detectable HAV RNA; 
565 (15%), 3,255 (84%), and 57 (<1%) of these specimens 
were genotype IA, IB, or IIIA, respectively. Adherence to the 
Advisory Committee on Immunization Practices (ACIP) 
recommendations to vaccinate populations at risk can help 
control the current increases and prevent future outbreaks of 
hepatitis A in the United States (7).
Hepatitis A infections among persons who meet the Council 
of State and Territorial Epidemiologists (CSTE) hepatitis A case 
definition (https://wwwn.cdc.gov/nndss/conditions/hepatitis-
a-acute/) are notified to CDC through the National Notifiable 
Diseases Surveillance System (NNDSS). Cases reported to 
CDC through NNDSS during 2013–2018 were used to 
calculate percent change (2013–2015 versus 2016–2018) by 
state and mapped using RStudio software (version 1.2.1335; 
RStudio, Inc.). Serum specimens from CSTE confirmed cases 
submitted to the CDC laboratory were tested for HAV RNA by 
polymerase chain reaction, and isolated virus was amplified to 
characterize a 315–base-pair fragment of the VP1/P2B region, 
which defines the genotype of the virus.
Overall, reports of hepatitis A cases increased 294% during 
2016–2018 compared with 2013–2015 (Figure). Eighteen 
states had lower case counts during 2016–2018 compared 
with 2013–2015. Nine states and Washington, DC had an 
increase of approximately 500%. During 2013–2018, 4,508 
HAV anti-immunoglobulin M–positive specimens under-
went additional testing at CDC. During 2013–2015, 226 
specimens underwent additional testing, of which 197 (87%) 
had detectable HAV RNA; of the RNA-positive specimens, 76 
(39%), 121 (61%), and 0 (0%) tested positive for a genotype 
IA, IB, or IIIA viral strain, respectively. In comparison, 4,282 
specimens were tested by CDC during 2016–2018, of which 
3,877 (91%) had detectable HAV RNA; 565 (15%), 3,255 
(84%), and 57 (<1%) of these specimens were genotype IA, 
IB, or IIIA, respectively.
Discussion
The number of hepatitis A infections reported to CDC 
increased during 2016–2018, along with the number of 
specimens from infected persons submitted to CDC for 
additional testing. In the past, outbreaks of hepatitis A virus 
infections occurred every 10–15 years and were associated 
with asymptomatic children (8). With the widespread adop-
tion of universal childhood vaccination recommendations 
(https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5507a1.
htm), asymptomatic children are no longer the main drivers 
of hepatitis A outbreaks (3,9). Although the overall incidence 
rate of HAV infections has decreased within all age groups, a 
large population of susceptible, unvaccinated adults who were 
not infected by being exposed to the virus during childhood 
remain vulnerable to infection by contaminated foods (typi-
cally imported from countries with endemic HAV transmis-
sion) and recently, on a much larger scale, through behaviors 
that increase risk for infection in certain vulnerable popula-
tions, such as drug use (3).
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FIGURE. Percent change in reported hepatitis A infections, by 
state — National Notifiable Diseases Surveillance System, United 
States, 2013–2015 and 2016–2018*
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>0–100
−100–0
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Abbreviation: DC = District of Columbia.
* 2017 and 2018 case counts are provisional.
Increasingly, molecular epidemiology is employed by public 
health laboratories to better characterize hepatitis A transmis-
sion patterns. When combined with reliable epidemiologic 
data, these laboratory data can be used to identify transmission 
networks and confirm the source of exposure during common-
source outbreaks, facilitating prompt and effective public 
health response. Historically, genotype IA has been the most 
common genotype circulating in North and South America. 
During 2013–2018, HAV genotype IB predominated in the 
United States. Increasing numbers of genotype IIIA were seen, 
a genotype that is considered rare in the United States.
Decreasing new infections from hepatitis A virus can be 
achieved and sustained by maintaining a high level of popu-
lation immunity through vaccination. There is no universal 
vaccination recommendation for adults in the United States; 
however, ACIP does recommend vaccination for adults who 
plan travel to HAV-endemic countries, MSM, persons who 
use drugs, persons with chronic liver disease, and recently, 
persons experiencing homelessness (7). Continued efforts to 
increase hepatitis A vaccination coverage among the ACIP-
recommended risk groups is vital to halting the current hepa-
titis A outbreaks and reducing overall hepatitis A incidence in 
the United States.
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Summary
What is already known about this topic?
Hepatitis A is a vaccine-preventable viral infection of the liver 
that is primarily transmitted through consumption of micro-
scopic amounts of feces.
What is added by this report?
During 2016–2018, reports of hepatitis A infections in the 
United States increased by 294% compared with 2013–2015, 
related to outbreaks associated with contaminated food items, 
among men who have sex with men, and primarily, among 
persons who report drug use or homelessness.
What are the implications for public health practice?
Increasing vaccination among groups at risk for hepatitis A infection 
might halt ongoing outbreaks and prevent future outbreaks.
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Disparities in Incidence of Human Immunodeficiency Virus Infection Among 
Black and White Women — United States, 2010–2016
Erin L.P. Bradley, PhD1,2; Austin M. Williams, PhD3; Shana Green, PhD1,2; Ashley C. Lima, PhD1,2;  
Angelica Geter, PhD1,2; Harrell W. Chesson, PhD3; Donna Hubbard McCree, PhD1
Incident human immunodeficiency virus (HIV) infec-
tions among adolescent females and women declined during 
2010–2016, with the largest decrease (21%) occurring among 
black women (1). However, in 2016, although black women 
accounted for 13% of the U.S. female population, 60% of 
new HIV infections among women were in black women, 
indicating persisting disparities (1). CDC used the population 
attributable proportion (PAP) disparity measure to describe the 
proportional decrease in HIV infection among black and white 
women combined that would be realized if the group with the 
higher rate (blacks) had the same rate as did the group with the 
lower rate (whites) (2). Analyses indicated that an estimated 
3,900 of 4,200 (93%) incident HIV infections among black 
women in 2016 would not have occurred if rates were the 
same for black and white women. The PAP disparity measure 
decreased from 0.75 in 2010 to 0.70 in 2016, suggesting that 
if incidence rates for black women were the same as those for 
white women, the annual number of incident HIV infections 
among black and white women would have been 75% lower in 
2010 and 70% lower in 2016. Continued efforts are needed to 
identify and address social and structural determinants associ-
ated with HIV-related disparities to eliminate these disparities 
and decrease HIV incidence among black women.
CDC calculated the PAP disparity measure to assess trends 
in HIV infection disparities among black and white women 
in the United States from 2010 to 2016. HIV incidence and 
prevalence estimates for women and adolescent females aged 
≥13 years from an HIV Supplemental Surveillance Report (1) 
were used to compare estimated incidence with the incidence 
had there been no racial disparity between blacks and whites 
(black-white disparity). The PAP disparity measure was calcu-
lated as the number of excess incident infections among black 
females divided by the total number of estimated incident 
infections among black and white females combined. Excess 
incident infections were determined as the estimated number 
of incident infections among black females minus the hypo-
thetical number of incident infections (infections among black 
females in the absence of a black-white rate disparity). The 
hypothetical number of incident infections was obtained by 
dividing the HIV incidence rate in white females by 100,000 
and then multiplying by the number of HIV-negative black 
females. To increase precision in the analyses because incident 
infection counts in the surveillance report were rounded to 
the nearest hundred, the estimated number of incident HIV 
infections was derived by dividing the surveillance report rate 
by 100,000, then multiplying by the number of females aged 
≥13 years. Rates of HIV infection were defined as the estimated 
number of incident infections divided by the number of HIV-
negative females aged ≥13 years, then multiplied by 100,000. 
This calculation was carried out for each year from 2010 to 
2016. To assess changes in the PAP disparity measure between 
the beginning and the end of the study period, a z-statistic 
was calculated to test for statistically significant differences 
between the 2010 and 2016 measures. The z-statistic was cal-
culated as the average difference between the 2016 and 2010 
PAP disparity measures in the simulated data divided by the 
standard error of those differences. Simulations consisted of 
10,000 calculations of the annual PAP measures, each using a 
random draw of the HIV incidence rate from a normal distri-
bution (approximated using the relative standard errors from 
the surveillance report) (3).
From 2010 to 2016, the estimated incidence of HIV infec-
tion among black women and adolescent females decreased 
from 32.5 per 100,000 persons to 24.4; the rate among white 
women and adolescent females did not differ in 2016 (1.6) 
compared with that in 2010 (1.6) and ranged from 1.4–1.7 
during that time. The PAP disparity measure decreased from 
0.75 in 2010 to 0.70 in 2016. This change suggests that if 
incidence rates for black women were the same as were those 
for white women, the annual number of incident cases of 
HIV infection among black and white women would have 
been 75% lower in 2010 and 70% lower in 2016 (Table). 
The 7% decrease in the PAP disparity measure from 2010 to 
2016 (p = 0.15) indicates that the percentage of incident HIV 
infections attributable to racial disparities between black and 
white women decreased by about 7% over this period. Thus, 
in 2016, an estimated 3,900 of 4,200 (93%) incident HIV 
infections among black women would not have occurred if 
rates were the same for black and white women.
Discussion
The declines in incidence of HIV infection among black 
women and adolescent females signal some progress toward 
reducing racial disparities among women, and these findings 
are consistent with previous research that indicated reductions 
in racial/ethnic disparities in diagnosis of HIV infection among 
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TABLE. Population attributable proportion (PAP) for human immunodeficiency virus (HIV) incidence among black and white women and 
adolescent females aged ≥13 years, by race — United States, 2010–2016
Year
No. of incident HIV infections* (rate†)
Excess infections  
among blacks PAP§
% Change  
2010 to 2016¶ P-valueBlacks Whites
2010 5,300 (32.5) 1,400 (1.6) 5,000 0.75 −7 0.15
2011 5,000 (30.7) 1,300 (1.5) 4,800 0.75
2012 4,700 (28.6) 1,300 (1.5) 4,500 0.74
2013 4,400 (26.0) 1,200 (1.4) 4,100 0.74
2014 4,000 (23.4) 1,300 (1.5) 3,700 0.70
2015 4,100 (23.7) 1,500 (1.7) 3,800 0.68
2016 4,200 (24.4) 1,400 (1.6) 3,900 0.70
* Number of incident infections from an HIV Surveillance Report (https://www.cdc.gov/hiv/library/reports/hiv-surveillance.html). Incident infection counts rounded 
to the nearest hundred.
† Infections per 100,000 population. To increase precision in the analyses, rates were calculated as the estimated number of incident HIV infections not rounded to 
the nearest hundred (surveillance report rate divided by 100,000, multiplied by the number of females aged ≥13 years) divided by the number of HIV-negative 
females aged ≥13 years, then multiplied by 100,000.
§ The PAP disparity measure reflects the percentage of HIV infections attributable to racial disparities in HIV incidence between black and white women and adolescent 
females aged ≥13 years. The PAP measure was calculated as the number of excess incident infections among black females divided by the total number of estimated 
incident infections among black and white females. Excess incident infections among black females refers to the estimated number of incident infections among 
black women minus the hypothetical number of incident infections that would have occurred among black women if their HIV incidence rate were the same as that 
of white women. The hypothetical number of incident infections in the absence of a black-white disparity in rates was calculated by dividing the HIV incidence rate 
in white females by 100,000 and multiplying by the HIV-negative black female population.
¶ The percent change from 2010 to 2016 was calculated as the difference between the 2016 and 2010 PAP values, divided by the 2010 PAP value.
women during 2010–2014 using different measures of dispar-
ity (absolute rate difference, diagnosis disparity ratio, and index 
of disparity) (4). However, notable black-white disparities 
among women persist. In 2016, an estimated 93% of incident 
HIV infections among black women would not have occurred 
if the incidence rate for black women were as low as the rate 
for white women. Estimates of the annual PAP disparity mea-
sure during 2010–2016 suggest that eliminating black-white 
disparities in incident HIV infections among women and 
adolescent females would have achieved a decrease in overall 
incidence among black and white women of 75% in 2010 
and 70% in 2016. This finding highlights the contribution of 
racial/ethnic disparities to overall HIV infection rates among 
women and adolescent females and underscores the importance 
of further reducing, or eliminating, these differences.
Reducing and monitoring HIV-related disparities are impor-
tant national goals (5). Tailored strategies to reduce disparities 
in incidence among women should address social and structural 
determinants, including inequitable access to health care, HIV-
related stigma, and comparatively high background prevalence 
of certain sexually transmitted infections (6,7), that increase 
the risk for HIV infection among black women. Because 
most HIV infections among black women occur through 
heterosexual transmission (1), strategies that also effectively 
engage heterosexual and bisexual men are important. Social 
and structural determinants create or sustain disparities in HIV 
infection, treatment, and care. For example, compared with 
their white counterparts, black women and men experience 
longer delays in diagnosis (8) and are less likely to be virally 
suppressed (i.e., <200 copies of viral RNA per mL of blood) 
(9,10). Targeted measures that address reducing transmission 
through viral suppression and preventing acquisition through 
biomedical and behavioral interventions (e.g., preexposure 
prophylaxis [PrEP] and condom use; and providing adequate 
treatment once HIV infection is diagnosed) will play important 
roles in reducing disparities.
The findings in this report are subject to at least five limita-
tions. First, estimates of HIV incidence are subject to model 
assumptions and data completeness (1). Second, only one 
measure of disparity was used, limiting a more comprehen-
sive analysis of racial/ethnic disparities in incidence of HIV 
infection among women and adolescent females. Using other 
measures of disparity could provide alternative results. Third, 
the p-value calculated for the 7% change in the PAP might be 
overestimated because it assumed no correlation in the error 
of estimated incidence within racial groups over time. This 
implies that the error in estimating the 2010 incidence among 
black women is unrelated to the error in estimating the 2016 
incidence among black women. Fourth, although the PAP 
disparity measure has a straightforward interpretation and 
quantifies excess HIV infections among black females, this 
study does not yield additional insight into what structural 
or policy changes are needed to eliminate disparities. Finally, 
incidence in only two racial groups was compared, whereas 
disparities might exist among other racial/ethnic groups.
Despite these limitations, findings from the PAP disparity 
measure analyses enhance the measurement of HIV disparities 
among women and adolescent females by quantifying the num-
ber of incident HIV infections that might have been prevented 
in the absence of racial disparities. This information lends 
support for strengthening HIV prevention and care efforts 
for heterosexual black females and males to continue progress 
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Summary
What is already known about this topic?
Rates of human immunodeficiency virus (HIV) infection among 
all women have declined since 2010, but rates among black 
women remain higher than do those among white women.
What is added by this report?
A population attributable proportion analysis found that in 
2016, an estimated 3,900 of 4,200 (93%) incident HIV infections 
among black women would not have occurred if the incidence 
for black women were the same as that for white women.
What are the implication for public health practice?
Reducing racial disparities among women is needed to achieve 
broader HIV control goals. Addressing social and structural 
determinants of health and applying tailored strategies to 
reduce HIV incidence in black women and their partners are 
important elements to achieving health equity.
toward closing the gap in racial disparities in HIV infection 
among women. Such gains are needed to achieve the U.S. 
Department of Health and Human Services’ goal of ending 
the HIV epidemic in the United States by 2030* and prevent 
deaths related to acquired immunodeficiency syndrome.
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Racial Disparities in Mortality Associated with Systemic Lupus 
Erythematosus — Fulton and DeKalb Counties, Georgia, 2002–2016
S. Sam Lim, MD1; Charles G. Helmick, MD2; Gaobin Bao, MPH1; Jennifer Hootman, PhD2;  
Rana Bayakly, MPH3; Caroline Gordon, MD4; Cristina Drenkard, MD, PhD1
Systemic lupus erythematosus (SLE) is a chronic, systemic 
autoimmune disease with often nonspecific symptoms that 
can lead to a delay in diagnosis. The disease disproportion-
ately affects women and minorities. Blacks with SLE also 
have more severe disease and develop it at an earlier age (1). 
Despite an increase in the 5-year survival rate from 50% in 
1955 to approximately 90% in the 2000s, attributed largely 
to advances in management of SLE (2), premature mortality 
among SLE patients persists, often as a result of disease severity, 
infections, and cardiovascular disease. Because existing SLE 
mortality estimates based on death certificate data are known 
to underestimate SLE deaths (3), SLE mortality was analyzed 
using 2002–2004 data from the population-based Georgia 
Lupus Registry (1). Incident and prevalent SLE cases matched 
to the National Death Index through 2016 identified 97 and 
401 deaths, respectively. Standardized mortality ratios adjusted 
for age group, sex, and race were two to three times higher 
among persons with SLE relative to expected deaths in the 
general population. Blacks had significantly higher cumulative 
mortality than did whites, and blacks with both incident and 
prevalent cases were significantly younger at death (mean age 
51.8 and 52.3 years, respectively) than were whites (mean age 
64.4 and 65.0 years, respectively). Whites had lower mortality 
after diagnosis than did blacks; among incident cases, mortality 
among whites did not occur until 5 years after SLE diagnosis, 
whereas blacks had significantly and persistently higher mor-
tality from the time of diagnosis. There were no significant 
differences by sex. Current CDC-supported efforts encourage 
early detection, diagnosis, and treatment, and enhanced self-
management skills to mitigate racial disparities and improve 
outcomes overall among persons with SLE.
The Georgia Lupus Registry (1) was designed to collect data on 
all residents of two Georgia counties (Fulton and DeKalb) in the 
Atlanta metropolitan area with large black and white populations. 
The public health surveillance exemption to the Health Insurance 
Portability and Accountability Act Privacy Rule (https://www.hhs.
gov/hipaa/for-professionals/privacy/index.html) allowed investiga-
tors to obtain protected health information (PHI) without written 
consent of the patient. Application of this exemption enabled 
investigators to ascertain all potential cases, determine whether 
potential cases met case definition criteria, and provide enough 
information to prevent duplicate counting of patients examined 
in multiple facilities. PHI was stored securely, and its use was 
limited to authorized research personnel, maximizing the use of 
deidentified data whenever feasible.
The primary sources of potential cases included hospitals, 
rheumatologists, nephrology groups, and dermatology groups 
in and around the two counties. Administrative databases were 
queried retrospectively for billing codes for lupus and related 
conditions. Secondary sources included laboratories (includ-
ing pathology laboratories) and queries in other population 
databases (1). Abstractors were trained and underwent regular 
quality assessments. The study was reviewed and approved by 
the Institutional Review Boards at Emory University and the 
Georgia Department of Public Health. CDC determined this 
study did not meet the definition of human subjects research 
(public health practice). SLE prevalence was estimated for 
2002 and incidence for 2002–2004 from the Georgia Lupus 
Registry. Denominator data for the two counties were obtained 
from postcensal population estimates. Age-adjusted estimates 
and 95% confidence intervals were calculated based on the 
standard 2000 projected age distribution (1).
A case of SLE was defined as meeting either the 1997 update 
of the 1982 American College of Rheumatology (ACR) revised 
classification criteria (meeting four or more of the 11 criteria*) 
(4,5) or an alternative definition (three of the ACR criteria plus 
a documented diagnosis of SLE by the patient’s board-certified 
rheumatologist). All incident and prevalent SLE cases were 
matched to the National Death Index through 2016. Cause 
of death codes were available but not analyzed because of poor 
reliability regarding SLE attribution (3). Standardized mortal-
ity ratios were calculated as the ratio of observed deaths among 
persons with prevalent SLE to expected deaths in the general 
county populations; subgroups were compared using the same 
age group, sex, and race categories. The number of expected 
deaths was calculated by multiplying the death rate of the general 
population in Fulton and DeKalb counties by the total number 
of SLE patients in each group. There were too few deaths to cal-
culate standardized mortality ratios for the incident SLE group. 
Cumulative mortality used Kaplan-Meier survival analysis for 
both incident and prevalent cases to determine the percentage 
* The 11 criteria are as follows: malar rash, discoid rash, photosensitivity, oral 
ulcers, arthritis, serositis (pericarditis or pleuritis), renal disorder, neurologic 
disorder, hematologic disorder, immunologic disorder, and antinuclear antibody. 
https://www.rheumatology.org/Portals/0/Files/1997%20Update%20of%20
1982%20Revised.pdf.
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of SLE patients dying since their diagnosis (1). Analyses were 
performed using SAS software (version 9.4; SAS Institute).
During 2002–2004, a total of 336 incident SLE cases were 
identified; these SLE patients were demographically similar 
to the patients in 1,353 cases with prevalent SLE in 2002 
(87%–90% female, 74%–76% black, and 23% white) but were 
older at SLE diagnosis (mean age 40.6 years) than were patients 
with prevalent SLE (34.6 years). Among patients with prevalent 
and incident SLE, 401 and 97 deaths, respectively, occurred 
through 2016. Standardized mortality ratios using 2002–2016 
data were 2.3–3.3 times higher for persons with prevalent SLE 
relative to expected deaths in the general population (Table). 
Black females with prevalent SLE were three times more 
likely to die than were black females in the general population 
(standardized mortality ratio = 3.38). Cumulative mortality 
was significantly higher among blacks than among whites for 
both incident (Figure 1) and prevalent (Figure 2) SLE; death 
occurred at a younger age among blacks with incident SLE 
cases (mean age = 51.8 ± 17.5 years) and prevalent SLE cases 
(mean 52.3 ± 15.9 years) than it did among whites (64.4 ± 18.9 
years and 65.0 ± 16.3 years, respectively) (p<0.001). Mortality 
among whites was markedly lower in the years immediately 
following diagnosis compared with mortality among blacks; 
among incident cases, no deaths were observed among whites 
until 5 years after SLE diagnosis, whereas mortality among 
blacks was persistently higher from the time of diagnosis. In 
addition, whites with SLE had the same cumulative mortal-
ity proportion (9%) in 10 years as that observed in blacks in 
2 years (Figure 1). There were no significant differences by sex.
TABLE. Standardized mortality ratios for patients with prevalent cases 
of systemic lupus erythematosus (SLE) from 2002 to 2016, adjusted 
by age, sex, and black/white race* — Georgia Lupus Registry
Characteristic
No. of SLE 
patients (%)
Deaths Standardized 
mortality ratio  
(95% CI)Observed Expected
Overall (black  
and white†)
1,335 (100) 400 128 3.12 (2.83–3.44)
Sex
Male 135 (10.1) 51 17 2.98 (2.27–3.92)
Female 1,200 (89.9) 349 111 3.14 (2.83–3.49)
Race
Black 1,024 (76.7) 324 97 3.34 (3.00–3.72)
White 311 (23.3) 76 31 2.43 (1.94–3.04)
Race/Sex (total = 1,200)
Black female 924 (77.0) 287 85 3.38 (3.01–3.79)
White female 276 (23.0) 62 26 2.36 (1.84–3.02)
Abbreviation: CI = confidence interval.
* Age on July 1 was used for adjustment. The standardized mortality ratio is a 
ratio between the observed number of deaths in those with SLE and the 
number of deaths expected, based on age, sex, and race specific rates in Fulton 
and DeKalb counties. CIs are based on a generalized estimating equation 
model with Poisson distribution.
† Eighteen persons who were not identified as black or white, including one 
who died, were excluded.
FIGURE 1. Cumulative mortality* of incident systemic lupus 
erythematosus (SLE)  cases diagnosed during 2002–2004, by 
black/white race — Georgia Lupus Registry, 2002–2016
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* Cumulative mortality for incident SLE cases was calculated using Kaplan-Meier 
survival analysis to indicate the probability of SLE patients dying at a specified 
time since diagnosis. Difference p = 0.008, by log rank test.
Discussion
Despite increasing awareness of SLE and advancements in 
treatment (6), mortality among persons with SLE remains 
high, with the highest standardized mortality ratio among 
black females. The effect of this racial disparity in mortality is 
further underscored by the fact that the prevalence of SLE in 
blacks is three times that in whites (1).
These findings are similar to those reported in a 2002 study, 
which also found a higher incidence and prevalence among 
women and blacks, but the current study used more accurate 
methods to ascertain cases (7). A recent nationwide study 
using causes of death from 1968 through 2013 obtained from 
death certificate data in CDC’s WONDER database (https://
wonder.cdc.gov) showed that age-standardized mortality rates 
decreased over time among SLE patients but remained high 
relative to non-SLE mortality, with the highest mortality rates 
in women, blacks, and residents of the South and West U.S. 
Census regions (8). Both of these studies depended solely on 
death certificates to identify cases of SLE, which only capture 
an estimated 40%–60% of SLE cases (3,9).
The findings in this report are subject to at least four limitations. 
First, racial identity was assigned based primarily on the physician’s 
assessment as documented in the medical record, which might not 
reflect the patient’s self-identity. Second, some cases might have 
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FIGURE 2. Cumulative mortality* of prevalent systemic lupus 
erythematosus (SLE)  cases diagnosed in 2002, by black/white race — 
Georgia Lupus Registry, 2002–2016
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* Cumulative mortality for prevalent SLE cases was calculated using Kaplan-
Meier survival analysis to indicate the probability of SLE patients dying at a 
specified time since 2002. Difference p = 0.025, by log rank test.
been missed in the original registry. Third, there might be vari-
ability in SLE diagnosis by rheumatologists, and undiagnosed cases 
were not sought. Finally, these results might not be generalizable 
outside the two counties. Strengths of the current study include 
the use of a population-based lupus registry identifying nearly all 
validated SLE cases in the two-county area and the long follow-
up period, resulting in data on more SLE deaths than would be 
identified by death certificate diagnoses alone.
Prioritizing the identification of reversible mortality factors 
and developing strategies to address them could aid in mitigat-
ing racial disparities and improving outcomes overall in SLE. 
The first-ever National Public Health Agenda for Lupus (10) 
describes a plan to address lupus from a public health perspec-
tive. Other CDC-supported, population-based lupus registries 
and longitudinal follow-up activities include examining natural 
history, treatment, access to care, and disparities as potential 
factors in SLE mortality and progression (https://www.cdc.
gov/lupus/funded/lupus-studies.htm). The Lupus Foundation 
of America and the American College of Rheumatology are 
working together to encourage early detection and treatment 
of lupus, enhance the self-management skills of patients with 
lupus, and improve health care providers’ ability to make accu-
rate diagnoses. Additional information is available at https://
www.cdc.gov/lupus/funded/awareness.htm.
Summary
What is already known about this topic?
Systemic lupus erythematosus (SLE) is a systemic autoimmune 
disease that disproportionately affects women and minorities. 
The 5-year survival rate of patients with SLE has been improving.
What is added by this report?
Using improved methods by following SLE patients carefully 
defined in a population-based registry, standardized mortality 
ratios were two to three times higher in persons with SLE than 
in the general population. Compared with whites with SLE, 
cumulative SLE mortality was significantly higher among blacks, 
with deaths occurring sooner after diagnosis and at a mean age 
approximately 13 years younger.
What are the implications for public health practice?
Current CDC-supported efforts to encourage early detection, 
diagnosis, and treatment, and to enhance self-management 
skills might mitigate racial disparities and improve overall 
outcomes in SLE.
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Abstract
Background: Approximately 700 women die from pregnancy-related complications in the United States every year.
Methods: Data from CDC’s national Pregnancy Mortality Surveillance System (PMSS) for 2011–2015 were analyzed. 
Pregnancy-related mortality ratios (pregnancy-related deaths per 100,000 live births; PRMRs) were calculated overall 
and by sociodemographic characteristics. The distribution of pregnancy-related deaths by timing relative to the end of 
pregnancy and leading causes of death were calculated. Detailed data on pregnancy-related deaths during 2013–2017 
from 13 state maternal mortality review committees (MMRCs) were analyzed for preventability, factors that contributed 
to pregnancy-related deaths, and MMRC-identified prevention strategies to address contributing factors.
Results: For 2011–2015, the national PRMR was 17.2 per 100,000 live births. Non-Hispanic black (black) women and 
American Indian/Alaska Native women had the highest PRMRs (42.8 and 32.5, respectively), 3.3 and 2.5 times as high, 
respectively, as the PRMR for non-Hispanic white (white) women (13.0). Timing of death was known for 87.7% (2,990) 
of pregnancy-related deaths. Among these deaths, 31.3% occurred during pregnancy, 16.9% on the day of delivery, 
18.6% 1–6 days postpartum, 21.4% 7–42 days postpartum, and 11.7% 43–365 days postpartum. Leading causes of 
death included cardiovascular conditions, infection, and hemorrhage, and varied by timing. Approximately sixty percent 
of pregnancy-related deaths from state MMRCs were determined to be preventable and did not differ significantly by 
race/ethnicity or timing of death. MMRC data indicated that multiple factors contributed to pregnancy-related deaths. 
Contributing factors and prevention strategies can be categorized at the community, health facility, patient, provider, 
and system levels and include improving access to, and coordination and delivery of, quality care.
Conclusions: Pregnancy-related deaths occurred during pregnancy, around the time of delivery, and up to 1 year postpartum; 
leading causes varied by timing of death. Approximately three in five pregnancy-related deaths were preventable.
Implications for Public Health Practice: Strategies to address contributing factors to pregnancy-related deaths can be 
enacted at the community, health facility, patient, provider, and system levels.
Introduction
Approximately 700 women die annually in the United States 
from pregnancy-related complications (1). Significant racial/
ethnic disparities in pregnancy-related mortality exist; black 
women have a pregnancy-related mortality ratio approximately 
three times as high as that of white women (2,3). Better 
understanding is needed on the circumstances surrounding 
pregnancy-related deaths and strategies to prevent future deaths.
This report describes the timing and characteristics of preg-
nancy-related deaths in the United States using 2011–2015 
national CDC Pregnancy Mortality Surveillance System 
(PMSS) data. Data from 13 state maternal mortality review 
committees (MMRCs) during 2013–2017 were used to 
determine the percentage of pregnancy-related deaths that 
were preventable and factors that contributed to the deaths. 
MMRC-identified strategies for prevention are reported.
Methods
PMSS was established in 1986 by CDC and the American 
College of Obstetricians and Gynecologists (ACOG) to evaluate 
the causes of death and risk factors associated with pregnancy-
related deaths. PMSS methodology has been described previ-
ously (2); CDC’s Division of Reproductive Health requests that 
all states, the District of Columbia, and New York City send 
death certificates, linked live birth or fetal death certificates, and 
additional data when available, on deaths that occurred during 
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Summary 
What is already known about this topic?
Approximately 700 women die annually in the United States from 
pregnancy-related complications.
What is added by this report?
Among pregnancy-related deaths for which timing was known, 
31.3% deaths occurred during pregnancy, 16.9% on the day of 
delivery, 18.6% on days 1–6 postpartum, 21.4% on 
days 7–42 postpartum, and 11.7% on days 43–365 postpartum. 
Leading causes of death varied by timing relative to the end of 
pregnancy. Approximately three in five pregnancy-related deaths 
were preventable. Contributing factors can be categorized at the 
community, health facility, patient, provider, and system levels.
What are the implications for public health practice?
Most pregnancy-related deaths are preventable, demonstrating 
the need to identify and implement strategies to address the 
multiple contributing factors.
pregnancy or within 1 year after delivery. Information on indi-
vidual deaths are reviewed by medically trained epidemiologists 
to determine the pregnancy-relatedness and cause (4). A death 
is determined to be pregnancy-related if the death was caused 
by a pregnancy complication, a chain of events initiated by 
pregnancy, or the aggravation of an unrelated condition by the 
physiologic effects of pregnancy. Cause of death coding includes 
the following 10 mutually exclusive categories: hemorrhage; 
infection; amniotic fluid embolism; thrombotic pulmonary or 
other embolism (i.e., air, septic, or fat); hypertensive disorders 
of pregnancy (i.e., preeclampsia or eclampsia)*; anesthesia 
complications; cerebrovascular accidents†; cardiomyopathy; 
other cardiovascular conditions (e.g., congenital heart disease, 
ischemic heart disease, cardiac valvular disease, hypertensive 
heart disease, and congestive heart failure); and other noncar-
diovascular medical conditions (e.g., endocrine, hematologic, 
immunologic, and renal).
Pregnancy-related death data from PMSS for 2011–2015 
were analyzed. The pregnancy-related mortality ratio (PRMR) 
is the number of pregnancy-related deaths per 100,000 live 
births. PRMRs were calculated by race/ethnicity, age, marital 
status, education, and year. Birth data, used for determining 
the number of live births, were obtained from U.S. natality 
files from the National Center for Health Statistics (5). SAS 
(version 9.4; SAS Institute) was used for all analyses. 
Cause and timing of pregnancy-related deaths were analyzed. 
Timing of death was identified as “during pregnancy” when 
* Deaths caused by hypertension that was not preeclampsia, eclampsia, or 
gestational hypertension were categorized in the “other cardiovascular 
conditions” category.
† Deaths caused by cerebrovascular accidents that were a result of preeclampsia or 
eclampsia were classified in the “hypertensive disorders of pregnancy” category; 
otherwise, deaths were classified in the “cerebrovascular accidents” category.
keywords on the death certificate noted the death was during 
pregnancy or the pregnancy checkbox option “pregnant at the 
time of death” was checked. Otherwise, timing of death in 
relation to the end of pregnancy was determined by comparing 
date of death on the death certificate with date of live birth 
or fetal death on linked birth or fetal death certificates. The 
specific timing of postpartum deaths was classified as unknown 
if there was no linked birth or fetal death certificate.
Data shared by 13 state MMRCs for deaths that occurred 
during 2013–2017§ were analyzed. Using a standardized data 
collection system, each multidisciplinary MMRC reviewed 
available data sources (e.g., medical records, social service 
records, autopsy reports, and vital records) to determine 
preventability, factors that contributed to the death, and 
prevention strategies to address contributing factors. Deaths 
attributable to suicide, drug overdose, homicide, and uninten-
tional injury were excluded from analyses. MMRCs used the 
following definition of preventability: “a death is considered 
preventable if the committee determines that there was some 
chance of the death being averted by one or more reason-
able changes to patient, community, provider, health facility, 
and/or system factors” (6). Percentage of deaths determined 
by MMRCs to have been preventable were calculated, and 
chi-squared tests were used to assess whether preventability 
differed by race/ethnicity or by timing of death. Thematic 
analyses of MMRC-identified factors that might have con-
tributed to deaths and strategies to prevent future deaths also 
were conducted.
Results
During 2011–2015, a total of 3,410 pregnancy-related deaths 
occurred in the United States; the overall PRMR was 17.2 
pregnancy-related deaths per 100,000 live births. The highest 
PRMRs were in women who were black (42.8) and American 
Indian/Alaska Native (32.5); these PRMRs were 3.3 and 
2.5 times as high, respectively, as were those in white women 
(13.0) (Table 1). The PRMR was highest among women aged 
≥35 years and women who were not married. The overall PRMR 
fluctuated by year, ranging from 15.9 (2012) to 18.0 (2014).
When combined, cardiovascular conditions were responsible 
for >33% of pregnancy-related deaths; these conditions include 
cardiomyopathy (10.8%), other cardiovascular conditions 
(15.1%), and cerebrovascular accidents (7.6%). Other leading 
causes of pregnancy-related death included other noncardio-
vascular medical conditions (14.3%), infection (12.5%), and 
obstetric hemorrhage (11.2%). The cause of death could not 
be determined for 6.7% of pregnancy-related deaths.
§ Arizona (2016), Colorado (2014–2015), Delaware (2013–2017), Florida 
(2017), Georgia (2013–2014), Hawaii (2015–2016), Illinois (2015), Mississippi 
(2016–2017), North Carolina (2014–2015), Ohio (2013–2016), South Carolina 
(2014–2017), Tennessee (2017), and Utah (2015–2016).
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Timing of death was known for 2,990 (87.7%) pregnancy-
related deaths. Among these deaths, 937 (31.3%) occurred 
during pregnancy, 506 (16.9%) on the day of delivery, 556 
(18.6%) 1–6 days postpartum, 640 (21.4%) 7–42 days post-
partum, and 351 (11.7%) 43–365 days postpartum (Table 2). 
Timing of deaths did not significantly differ between black and 
white women for most periods; however, a greater proportion 
of deaths among black women (14.9%) occurred 43–365 days 
postpartum compared to the proportion of deaths  among white 
women (10.2%) that occurred during the same period (p<0.01).
Distribution of timing of death varied by cause of death 
(Table 2). Most deaths caused by amniotic fluid embolism 
occurred on the day of delivery or within 6 days postpartum. 
Approximately 60% of deaths caused by hypertensive disorders 
of pregnancy occurred 0–6 days postpartum, whereas those 
caused by cerebrovascular accidents occurred most frequently 
1–42 days postpartum. Deaths caused by cardiomyopathy most 
commonly occurred 43–365 days postpartum; deaths caused 
by other cardiovascular conditions occurred most commonly 
during pregnancy and within 42 days postpartum.
The leading causes of death also varied by time relative to the 
end of pregnancy. During pregnancy, other noncardiovascular 
and other cardiovascular conditions were the leading causes of 
death (Figure); on the day of delivery, hemorrhage and amniotic 
fluid embolism were the major causes of death. Hemorrhage, 
hypertensive disorders of pregnancy, and infection were lead-
ing causes of death during the first 6 days postpartum. From 
6 weeks postpartum (43 days) through the end of the first year 
(365 days), cardiomyopathy was the leading cause of death.
Among 251 pregnancy-related deaths evaluated for prevent-
ability by the 13 MMRCs, a determination was made for 232 
(92.4%). Among these, 139 (60.0%) were determined to be 
preventable deaths. Preventability did not significantly differ 
between black and white women (p = 0.4), or between Hispanic 
and white women (p = 0.7), with 57.4% of deaths among 
black women, 62.7% among white women, and 58.3% among 
Hispanic women determined to be preventable. Preventability 
was also similar by timing of pregnancy-related death (59.0% 
during pregnancy, 53.3% during delivery, 57.1% 1–6 days 
postpartum, 66.7% 7–42 days postpartum, and 61.9% 
43–365 days postpartum; [p = 0.8]).
MMRCs identified an average of three to four contributing 
factors and two to three prevention strategies per pregnancy-
related death. Contributing factors were thematically coded 
as community factors (e.g., unstable housing and limited 
access to transportation); health facility factors (e.g., limited 
experience with obstetric emergencies and lack of appropriate 
personnel or services); patient factors (e.g., lack of knowledge 
of warning signs and nonadherence to medical regimens); 
provider factors (e.g., missed or delayed diagnosis and lack of 
TABLE 1. Pregnancy-related deaths, by sociodemographic 
characteristics — Pregnancy Mortality Surveillance System, 
United States, 2011–2015
Characteristic
No. of 
pregnancy-
related deaths
Pregnancy-
related 
mortality ratio*
Total 3,410 17.2
Race/Ethnicity† (N = 3,400)
White 1,385 13.0
Black 1,252 42.8
American Indian/Alaska Native 62 32.5
Asian/Pacific Islander 182 14.2
Hispanic 519 11.4
Age group (yrs) (N = 3,409)
<20 158 11.3
20–24 543 12.1
25–29 751 13.2
30–34 799 15.3
35–39 706 28.7
≥40 452 76.5
Highest level of education (N = 2,938)
Less than high school 572 19.8
High school graduate 1,090 24.2
Some college 775 14.8
College graduate or higher 501 9.4
Marital status (N = 3,371)
Married 1,543 13.1
Not married 1,828 22.8
Year
2011 702 17.8
2012 627 15.9
2013 679 17.3
2014 718 18.0
2015 684 17.2
* Number of pregnancy-related deaths per 100,000 live births.
† Women identified as white, black, American Indian/Alaska Natives, or Asian/
Pacific Islanders were not Hispanic. Hispanic women could be of any race.
continuity of care); and system-level factors (e.g., inadequate 
access to care and poor case coordination) (Table 3). MMRC-
identified prevention strategies addressing community factors 
included expanding clinical office hours and the number of 
providers who accept Medicaid, prioritizing pregnant and post-
partum women for temporary housing programs, and improv-
ing access to transportation. Actions addressing health facility 
factors included implementing obstetric emergency protocols 
and simulation training, providing telemedicine for facilities 
without on-site obstetric expertise, and implementing systems 
to foster communication among multiple providers. Although 
patient-level contributing factors were commonly identified, 
prevention strategies to mitigate these factors are often reliant 
upon providers and health systems. For example, prevention 
strategies to address patient-level factors included improving 
patient education materials and providing home health and 
patient support services. Provider-level prevention strategies 
included offering provider education to reduce missed or delayed 
diagnoses, implementing a maternal early warning system (7), 
and improving hand-off communication between obstetricians 
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TABLE 2. Pregnancy-related deaths, by cause of death and time of death relative to the end of pregnancy — Pregnancy Mortality Surveillance 
System, United States, 2011–2015*
Cause of death†
Time of death relative to the end of pregnancy§
Total no. 
of deaths
No. (%) attributed to each cause (row %)
During 
pregnancy
Day of 
delivery
1–6 days 
postpartum
7–42 days 
postpartum
43–365 days 
postpartum
Hemorrhage 72 (21.9) 123 (37.4) 105 (31.9) 27 (8.2) 2 (0.6) 329
Infection 117 (32.5) 17 (4.7) 83 (23.1) 121 (33.6) 22 (6.1) 360
Amniotic fluid embolism 12 (6.9) 114 (65.9) 42 (24.3) 4 (2.3) 1 (0.6) 173
Thrombotic pulmonary or other embolism 115 (40.9) 24 (8.5) 41 (14.6) 69 (24.6) 32 (11.4) 281
Hypertensive disorders of pregnancy 23 (10.8) 41 (19.3) 94 (44.3) 44 (20.8) 10 (4.7) 212
Anesthesia complications 2 (20.0) 3 (30.0) 3 (30.0) 2 (20.0) 0 10
Cerebrovascular accidents 68 (29.8) 9 (3.9) 49 (21.5) 79 (34.6) 23 (10.1) 228
Cardiomyopathy 48 (15.6) 21 (6.8) 25 (8.1) 75 (24.4) 138 (45.0) 307
Other cardiovascular conditions 173 (37.6) 65 (14.1) 61 (13.3) 110 (23.9) 51 (11.1) 460
Other noncardiovascular medical conditions 225 (52.7) 61 (14.3) 27 (6.3) 59 (13.8) 55 (12.9) 427
Unknown 82 (40.4) 28 (13.8) 26 (12.8) 50 (24.6) 17 (8.4) 203
Total 937 (31.3) 506 (16.9) 556 (18.6) 640 (21.4) 351 (11.7) 2,990
* Deaths in which timing of death was unknown were excluded (n = 420). 
† Cause of death categories are mutually exclusive. 
§ Time of death might be distant from onset of disease or initial event leading to death. 
and other providers. MMRC-identified prevention strategies 
addressing system-level factors included developing policies to 
ensure that women deliver at a health facility with an appropriate 
level of maternal care and extending Medicaid coverage for 
pregnant women to include 1 year of postpartum care.
Discussion
Pregnancy-related deaths occur not only during delivery 
but also during pregnancy and up to 1 year postpartum. The 
leading causes of pregnancy-related deaths varied by timing of 
death. Acute obstetric emergencies such as hemorrhage and 
amniotic fluid embolism most commonly occurred on the day 
of delivery, whereas deaths caused by hypertensive disorders of 
pregnancy and thrombotic pulmonary embolism most com-
monly occurred 0–6 days postpartum, and during pregnancy 
and 1–42 days postpartum, respectively. Cardiomyopathy 
was the most common cause of death in the late postpartum 
period (43–365 days postpartum). The higher proportion of 
pregnancy-related deaths in the late postpartum period among 
black women is likely attributable to higher proportion of 
pregnancy-related deaths due to cardiomyopathy among these 
women (8). Approximately three in five pregnancy-related 
deaths were determined by MMRCs to be preventable, and 
preventability did not differ significantly by race/ethnicity or 
timing of death. Recognizing the major causes of death by 
timing can help identify opportunities for intervention.
These data demonstrate the need to address the multiple 
factors that contribute to pregnancy-related deaths during 
pregnancy, labor and delivery, and postpartum. No single 
intervention is sufficient; reducing pregnancy-related deaths 
requires reviewing and learning from each death, improving 
women’s health, and reducing social inequities across the life 
span, as well as ensuring quality care for pregnant and postpar-
tum women (9). Throughout the preconception, pregnancy, 
and postpartum periods, providers and patients can work 
together to optimally manage chronic health conditions (10). 
Standardized approaches to addressing obstetric emergencies 
can be implemented in all hospitals that provide delivery 
services. The Alliance for Innovation on Maternal Health 
(AIM) has provided sets of bundled guidance to provide for 
such standardization.¶ Implementation of this guidance is 
often supported by perinatal quality collaboratives, state-based 
initiatives that aim to improve the quality of care for moth-
ers and infants (11). Ensuring that pregnant women at high 
risk for complications receive care in facilities prepared to 
provide the required level of specialized care also can improve 
outcomes; professional organizations have developed criteria 
for recommended levels of maternal care (12). CDC has cre-
ated the Levels of Care Assessment Tool (LOCATe) for public 
health decision makers to evaluate risk-appropriate care (13). 
In the postpartum period, follow-up care is critical for all 
women, particularly those with chronic medical conditions 
and complications of pregnancy (e.g., hypertensive disorders 
of pregnancy). ACOG recommends that postpartum women 
have contact with obstetric providers within the first 3 weeks 
postpartum and recognizes postpartum care as an ongoing 
process tailored to each woman’s individual needs (14). 
The findings in this report are subject to at least four limita-
tions. First, errors in reported pregnancy status on the death 
certificates have been described, potentially leading to overesti-
mation or underestimation of the number of pregnancy-related 
deaths (15). Second, data for specified race or Hispanic-origin 
groups other than non-Hispanic white and non-Hispanic black 
¶ https://safehealthcareforeverywoman.org/aim-supported-patient-safety-bundles.
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FIGURE. Three most frequent causes of pregnancy-related deaths, by time relative to the end of pregnancy — Pregnancy Mortality Surveillance 
System, United States, 2011–2015
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should be interpreted with caution because of inconsistencies 
in reporting these data on death certificates and surveys. Third, 
generally the pregnancy-relatedness cannot be determined in 
PMSS for injury deaths such as drug overdoses, suicides, or 
homicides, or for cancer-related deaths, because of limited infor-
mation concerning death circumstances. As such, these types 
of death are often not included in the PRMR. For consistency 
among data sources, these conditions were not investigated in 
MMRC data, although MMRC data have found suicides and 
drug overdoses to be a leading underlying cause of pregnancy-
related mortality (6). Most (75.0%) of these deaths occur in 
the late postpartum period. Finally, not all preventable deaths 
reported by MMRCs had a prevention strategy to address 
contributing factors; improving quality, completeness, and 
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TABLE 3. Maternal Mortality Review Committee–identified contributing factors and strategies to prevent future pregnancy-related deaths — 
Maternal Mortality Review Committees, 13 states, 2013–2017
Level Contributing factor Strategies to address contributing factor
Community Access to clinical care Expand office hours, increase number of providers who accept Medicaid, increase availability and use of group 
prenatal care programs
Unstable housing Prioritize pregnant and postpartum women for temporary housing programs
Lack of, or inadequate, 
transportation options
Strengthen or build systems to link persons to affordable transportation, or provide vouchers for transport to 
medical appointments
Improve availability of transportation services covered by Medicaid
Obesity and associated chronic 
disease complications
Improve access to healthy foods and enhance efforts to educate and promote healthy eating habits and weight 
management strategies
Health facility Limited experience with 
obstetric emergencies
Implement obstetric emergency simulation training for emergency department and obstetric staff members
Ensure emergency department staff members ask about recent pregnancy history and consult with obstetrician 
on call if patient is pregnant or has recently been pregnant
Lack of appropriate personnel 
or services
Provide telemedicine for facilities with no obstetric provider on-site
Ensure Medicaid managed care organizations’ contracts include sufficient access to specialists for patients at 
high risk
Lack of guiding protocols or 
tools to help ensure quality 
care provision
Ensure sepsis, hemorrhage, and massive transfusion protocols are in place and followed by staff members
Implement applicable patient safety bundles
Implement systems to foster communication among multiple providers to ensure proper case coordination
Implement protocols for using patient navigators
Patient/Family Lack of knowledge of warning 
signs or need to seek care
Improve counseling and use of patient education materials on warning signs and when to seek care, such as 
AWHONN Save Your Life discharge instructions
Implement a public education campaign to increase awareness of signs and symptoms of common 
complications
Nonadherence to medical 
regimens or advice
Standardize patient education to ensure providers relay consistent messages and implement techniques for 
ensuring patient understanding, such as patient “teaching back” to the provider
Make education materials available in the clinic and online
Strengthen and expand access to patient navigators, case managers, and peer support
Ensure access to interpreter services when needed
Offer home health or social work follow-up services
Provider Missed or delayed diagnosis Repeat blood pressure measurement in a timely (and possibly manual) manner when initial blood pressure result 
is unexpected
Offer provider education on cardiac conditions in pregnant and postpartum women
Perform thorough evaluation of patients reporting pain and shortness of breath
Inappropriate or delayed 
treatment
Only perform cesarean deliveries when medically indicated
Implement a maternal early warning system
Lack of continuity of care Improve care transition communication among obstetrician-gynecologists and other primary and specialty care 
physicians
System Inadequate receipt of care Develop policies to ensure pregnant women are transported to a hospital with an appropriate level of 
maternal care
Enlist state perinatal quality collaboratives to identify quality improvement procedures and periodic drills/
simulation training for birth facilities, including obstetric emergency drills
Design education initiatives for emergency department staff members on the care of pregnant and postpartum 
women
Case coordination or 
management
Extend expanded Medicaid coverage eligibility for pregnant women to include 1 year of postpartum care
Create quality improvement entity to manage outpatient care gaps and improve care coordination
Implement a postpartum care transition bundle for better integration of services for women at high risk
Develop procedures for all hospitals to improve documentation of abnormal test results, plan for follow-up care, 
and management of conditions
Develop universal health record system that allows for sharing of medical records among hospitals
Guiding policies, procedures, 
or standards not in place
Develop protocol for timely referrals and consults
Ensure all hospitals within a health care system follow the same protocols and policies
Abbreviation: AWHONN = Association of Women’s Health, Obstetric and Neonatal Nurses. 
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timeliness of MMRC data can translate into opportunities for 
prevention. MMRC-identified prevention strategies are based 
on comprehensive case review by a multidisciplinary group of 
clinical and nonclinical experts and might not always be drawn 
from published evidence-based interventions, in part because 
of a lack of programmatic and policy-based evidence. MMRCs’ 
access to comprehensive medical and social service records high-
lights their unique and critical role in understanding all factors 
contributing to pregnancy-related deaths and using those data 
to identify strategies to potentially prevent future deaths and 
contribute to the evidence base.
Pregnancy-related deaths occur during pregnancy, around the 
time of delivery, and within 1 year postpartum; leading causes 
of death vary by timing of death. Most pregnancy-related deaths 
can be prevented. Comprehensive review of pregnancy-related 
deaths can identify contributing factors and opportunities to 
implement strategies for preventing future deaths.
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QuickStats
FROM THE NATIONAL CENTER FOR HEALTH STATISTICS
Age-Adjusted Percentages* of Persons of All Ages  
Who Delayed Seeking Medical Care in the Past 12 Months Because of  
Worry About Cost,† by U.S. Census Region§ of Residence —  
National Health Interview Survey,¶ 2012 and 2017
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* With 95% confidence intervals indicated with error bars. 
† Based on a response to the question “During the past 12 months, has [person] delayed seeking medical care 
because of worry about the cost?” This question excluded dental care. Respondents were asked the question 
regarding themselves and other family members of all ages living in the same household. 
§ Northeast: Connecticut, Maine, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Rhode 
Island, and Vermont; Midwest: Illinois, Indiana, Iowa, Kansas, Michigan, Minnesota, Missouri, Nebraska, North 
Dakota, Ohio, South Dakota, and Wisconsin; South: Alabama, Arkansas, Delaware, District of Columbia, Florida, 
Georgia, Kentucky, Louisiana, Maryland, Mississippi, North Carolina, Oklahoma, South Carolina, Tennessee, 
Texas, Virginia, and West Virginia; West: Alaska, Arizona, California, Colorado, Hawaii, Idaho, Montana, Nevada, 
New Mexico, Oregon, Utah, Washington, and Wyoming.
¶ Estimates are based on household interviews of a sample of the civilian, noninstitutionalized U.S. population 
and are derived from the National Health Interview Survey Family Core component. Estimates are age-adjusted 
using the projected 2000 U.S. population as the standard population and using five age groups: 0–11, 12–17, 
18–44, 45–64, and ≥65 years.
 The percentage of persons of all ages who delayed seeking medical care in the past 12 months because of worry about the cost 
decreased from 8.2% in 2012 to 6.3% in 2017, and this pattern was consistent in each U.S. Census region of residence. Delays in 
seeking medical care because of worry about the cost declined from 5.8% to 4.4% in the Northeast, from 8.4% to 6.6% in the 
Midwest, from 8.7% to 7.3% in the South, and from 9.1% to 5.9% in the West. In both 2012 and 2017, persons of all ages living 
in the Northeast were the least likely to delay medical care because of worry about the cost. 
Sources: Summary Health Statistics for the U.S. Population, National Health Interview Survey, 2012. https://www.cdc.gov/nchs/data/series/
sr_10/sr10_259.pdf.
Tables of Summary Health Statistics, 2017. https://ftp.cdc.gov/pub/Health_Statistics/NCHS/NHIS/SHS/2017_SHS_Table_P-9.pdf.
Reported by: Jacqueline W. Lucas, MPH, jbw4@cdc.gov, 301-458-4355.
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